ARF1 and prostate carcinoma: LM11 impairs Arf1 activation more strongly than Exo2 in cancer cells [21]; therefore, our follow-up investigations will be focused on studying LM11 efficacy and its potential synergistic effects with salirasib in prostate cancer.